Education
About Us
Working with TipRanks
Follow Us
Avadel Pharmaceuticals (AVDL)
NASDAQ:AVDL
AVDL Stock Chart & Stats
$21.32
-$0.16(-1.47%)
At close: 4:00 PM EST
$21.32
-$0.16(-1.47%)
Day’s Range― - ―
52-Week Range$6.38 - $23.57
Previous CloseN/A
Volume358.54K
Average Volume (3M)2.53M
Market Cap
$2.09B
Enterprise Value$1.49B
Total Cash (Recent Filing)$91.58M
Total Debt (Recent Filing)$37.38M
Price to Earnings (P/E)―
Beta0.98
Next Earnings
Mar 09, 2026EPS Estimate
0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding97,817,590
10 Day Avg. Volume2,237,943
30 Day Avg. Volume2,532,743
Financial Highlights & Ratios
PEG Ratio0.27
Price to Book (P/B)13.54
Price to Sales (P/S)5.91
P/FCF Ratio-21.32
Enterprise Value/Market Cap0.71
Enterprise Value/Revenue6.00
Enterprise Value/Gross Profit6.36
Enterprise Value/Ebitda147.31
Forecast
1Y Price Target
$20.29Price Target Upside-4.83% Downside
Rating ConsensusHold
Number of Analyst Covering10
EPS Forecast (FY)0.19
Revenue Forecast (FY)$274.36M
Bulls Say, Bears Say
Bulls Say
Earnings GrowthAvadel Pharmaceuticals posted strong 2Q25 results with sales of $68.1 million, exceeding prior expectations and leading to an increased FY25 guidance.
Market ExpansionThe once-nightly oxybate (Lumryz) has been well received in the market, and it is expected to continue to expand the oxybate market and take additional market share.
Strategic AcquisitionsThe acquisition is intended to immediately advance Alkermes into the sleep space by bringing in Avadel’s commercial product LUMRYZ, and leveraging Avadel’s commercial infrastructure and experience in the sleep business.
Bears Say
Competitive PressuresThe looming advent of sodium oxybate generics next year may also pressure pricing in the oxybate class.
Market Performance DowngradeDowngrading to market perform and removing PT.
Regulatory Approval RisksThe Lundbeck proposal is subject to various closing conditions, including Avadel shareholder approval and regulatory approvals.
Avadel Pharmaceuticals News
AVDL FAQ
What was Avadel Pharmaceuticals’s price range in the past 12 months?
Avadel Pharmaceuticals lowest stock price was $6.38 and its highest was $23.57 in the past 12 months.
What is Avadel Pharmaceuticals’s market cap?
Avadel Pharmaceuticals’s market cap is $2.09B.
When is Avadel Pharmaceuticals’s upcoming earnings report date?
Avadel Pharmaceuticals’s upcoming earnings report date is Mar 09, 2026 which is in 89 days.
How were Avadel Pharmaceuticals’s earnings last quarter?
Avadel Pharmaceuticals released its earnings results on Nov 04, 2025. The company reported $0 earnings per share for the quarter, missing the consensus estimate of $0.059 by -$0.059.
Is Avadel Pharmaceuticals overvalued?
According to Wall Street analysts Avadel Pharmaceuticals’s price is currently Overvalued.
Does Avadel Pharmaceuticals pay dividends?
Avadel Pharmaceuticals does not currently pay dividends.
What is Avadel Pharmaceuticals’s EPS estimate?
Avadel Pharmaceuticals’s EPS estimate is 0.1.
How many shares outstanding does Avadel Pharmaceuticals have?
Avadel Pharmaceuticals has 97,817,590 shares outstanding.
What happened to Avadel Pharmaceuticals’s price movement after its last earnings report?
Avadel Pharmaceuticals reported an EPS of $0 in its last earnings report, missing expectations of $0.059. Following the earnings report the stock price went up 0.317%.
Which hedge fund is a major shareholder of Avadel Pharmaceuticals?
Currently, no hedge funds are holding shares in AVDL
Avadel Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$20.29 (-4.83% Downside)
$20.29 (-4.83% Downside)
Blogger Sentiment
Bullish
AVDL Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 2.2%
Last 30 Days ▲ 4.1%
Last 30 Days ▲ 4.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
114.47%
12-Months-Change
Fundamentals
Return on Equity
-0.32%
Trailing 12-Months
Asset Growth
26.03%
Trailing 12-Months
Company Description
Avadel Pharmaceuticals
Avadel Pharmaceuticals (AVDL) is a biopharmaceutical company focused on developing and commercializing innovative therapies for patients with central nervous system disorders. The company specializes in the field of sleep medicine and is known for its proprietary drug delivery technology, which allows for the development of unique formulations that can enhance the efficacy and safety of existing medications. Avadel's core products include its lead product, FT218, a once-nightly formulation of sodium oxybate, aimed at treating narcolepsy, along with a pipeline of other therapeutic candidates targeting various sleep disorders.
AVDL Company Deck
AVDL Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment with significant growth in patient demand, strong financial performance, and successful litigation outcomes. Although there are some concerns regarding pending royalty determinations and increased operating expenses, the positive aspects significantly outweigh the lowlights, indicating a strong position for future growth.View all AVDL earnings summariesAVDL Stock 12 Month Forecast
Average Price Target
$20.29
▼(-4.83% Downside)
Technical Analysis
Pacira Pharmaceuticals
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Evotec AG
―
Harrow Health
―
Ownership Overview
1.06% Insiders
13.36% Mutual Funds
35.35% Other Institutional Investors
39.00% Public Companies and Individual Investors